Skip to content

Comparision of two new ocular scanning refraction instruments

A prospective, open-labelled, multiple group, randomised, instrument validation clinical trial measuring central and peripheral refractive errors and higher order aberrations in healthy volunteers using two instruments: EyeMapper and HS Scanner with undilated and dilated pupils.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611001103954
Acronym
N/A
Enrollment
47
Registered
2011-10-24
Start date
2011-10-27
Completion date
2011-11-17
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To cross-validate two new peripheral aberrometers: the EyeMapper and the Hartmann-Shack (HS) Scanner with dilated and undilated pupils.

Interventions

Participants will be required to attend one visit. For the EyeMapper instrument, the participant’s head will be positioned on a chin rest and look at an internal fixation target. No contact will be made with the eye at any time. Following alignment, measurement is taken. Five consecutive measurements will be performed per instrument. Overall duration of measurements will be 10 minutes

Sponsors

Brien Holden Vision Institute
Lead SponsorCharities/Societies/Foundations

Study design

Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent. Be at least 18 years old, male or female. Willing to comply with the clinical trial visit schedule as directed by the Investigator. Have ocular health findings considered to be “normal”. Spherical equivalent refractive error between +1.50D and -4.00D (with astigmatism less than 4.00D)

Exclusion criteria

Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses. Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial. Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. NB: Systemic antihistamines are allowed on an “as needed basis”, provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used. Eye surgery within 12 weeks immediately prior to enrolment for this trial. Previous corneal refractive surgery. Rigid gas permeable or orthokeratology lens wear in the past month. Known allergy or intolerance to ingredients in any of the clinical trial products. Currently enrolled in another clinical trial. Participation in a clinical trial within the previous 24 hours for dispensing studies and in-house studies.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026